Incyte Corporation drugs
5 results
Jakafi (ruxolitinib)
(ruxolitinib)Incyte Corporation
Usage: Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute graft-versus-host disease in patients aged 12 and older. It also treats chronic graft-versus-host disease after failure of one or two prior systemic therapies in the same age group.
Niktimvo (axatilimab-csfr)
(axatilimab-csfr)Incyte Corporation
Usage: NIKTIMVO is indicated for treating chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, after they have failed at least two prior lines of systemic therapy.
Opzelura (ruxolitinib)
(ruxolitinib)Incyte Corporation
Usage: OPZELURA is indicated for the short-term treatment of mild to moderate atopic dermatitis in patients aged 12 and older, and for treating nonsegmental vitiligo in patients 12 and older. It should not be used with therapeutic biologics or other JAK inhibitors.
Pemazyre (pemigatinib)
(pemigatinib)Incyte Corporation
Usage: PEMAZYRE is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement, and for those with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. Approved under accelerated approval based on response rates.
Zynyz (retifanlimab-dlwr)
(retifanlimab-dlwr)Incyte Corporation
Usage: ZYNYZ is indicated for treating adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This approval is based on tumor response rates and may be contingent upon further confirmation of clinical benefit in ongoing trials.